TNFRSF1B and myeloid sarcoma: These data suggest that therapeutic strategies that antagonize TNFR1 to limit inflammation and augment TNFR2 signaling to enhance remyelination might provide effective treatments that both ameliorate disease and promote recovery in MS patients.